<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836546</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-0039</org_study_id>
    <nct_id>NCT04836546</nct_id>
  </id_info>
  <brief_title>Eversense® Non-adjunctive Use Post Approval Study</brief_title>
  <acronym>NA-PAS</acronym>
  <official_title>A Post Approval Study to Evaluate the Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System Used Non-adjunctively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Senseonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Senseonics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study&#xD;
      (patient serving as their own control), to evaluate the effectiveness of diabetes with the&#xD;
      Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG)&#xD;
      using a blood glucose (BG) meter in participants with either Type 1 or Type 2 diabetes.&#xD;
      Subjects will serve as their own control, with their baseline based on using SMBG to manage&#xD;
      their diabetes for the first 6 months followed by using Eversense CGM System non-adjunctively&#xD;
      for the second 6 months. Total follow-up duration is 12 months. The investigation will&#xD;
      include both clinic visits and home use of Eversense CGM System. The nonadjunctive phase will&#xD;
      have two sensors, up to 90-day duration, inserted sequentially. All care decisions specific&#xD;
      to diabetes will be based on blood glucose (BG) values in the first phase and the Eversense&#xD;
      CGM system values in the second phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis events</measure>
    <time_frame>First 6 months (phase 1) compared to second 6 months (phase 2)</time_frame>
    <description>Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis events with SMBG use for 6 months compared to Eversense CGM system used non-adjunctively for 6 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">925</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Self monitoring of blood glucose, then CGM System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will first manage their diabetes with SMBG for 6 months followed by managing their diabetes with Eversense CGM system for the next 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose meter</intervention_name>
    <description>First phase: SMBG for 6 months</description>
    <arm_group_label>Self monitoring of blood glucose, then CGM System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eversense CGM System</intervention_name>
    <description>Second phase: CGM for 6 months</description>
    <arm_group_label>Self monitoring of blood glucose, then CGM System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has diabetes&#xD;
&#xD;
          2. Subject is ≥18 years of age&#xD;
&#xD;
          3. Subject has a smartphone that is internet enabled&#xD;
&#xD;
          4. Subject is able to comply with study protocol tasks and understand written and verbal&#xD;
             instructions in the investigator's opinion&#xD;
&#xD;
          5. Subjects is willing and able to provide written signed and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is critically ill or hospitalized&#xD;
&#xD;
          2. Prior use of CGM defined as:&#xD;
&#xD;
               -  No more than 1 week of continuous CGM use in the last 6 months, and&#xD;
&#xD;
               -  At least 4 weeks of continuous use of CGM in the last 12 months or 12 weeks total&#xD;
                  use in the past 3 years.&#xD;
&#xD;
          3. Subject has a known contraindication to dexamethasone or dexamethasone acetate&#xD;
&#xD;
          4. Subjects requiring intravenous mannitol or mannitol irrigation solutions&#xD;
&#xD;
          5. Subject is on dialysis at the time of enrollment&#xD;
&#xD;
          6. Female subjects who are pregnant, planning on becoming pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pamela Mann, RN</last_name>
    <phone>240-778-6164</phone>
    <email>pamela.mann@senseonics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Tweden, PhD</last_name>
    <email>katherine.tweden@senseonics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Denver Endocrinology, Diabetes &amp; Thyroid Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Mitchell, CRC</last_name>
      <phone>303-321-2644</phone>
      <email>Stacey.Mitchell@denverendocenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Hang, CRC</last_name>
      <phone>3033212644</phone>
      <phone_ext>214</phone_ext>
      <email>Amanda@denverendocenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lori Gerard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Buckley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMR of Greater New Haven</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Capasso</last_name>
      <phone>203-490-2077</phone>
      <email>mcapasso@chasemr.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Soufer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Aliu</last_name>
      <phone>203-721-6040</phone>
      <email>aaliu@chasemr.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Soufer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Diabetes and Endocrine Care</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie-Ann Silvia</last_name>
      <phone>954-963-7191</phone>
      <phone_ext>243</phone_ext>
      <email>csilvia@diabetes-endocare.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Martin</last_name>
      <phone>954-963-7100</phone>
      <phone_ext>236</phone_ext>
      <email>mmartin@diabetes-endocare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sam Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Childs</last_name>
      <phone>404-355-4393</phone>
      <email>bchilds@atlantadiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Bode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Hardee</last_name>
      <phone>208-522-6005</phone>
      <email>william.hardee@idahomed.com</email>
    </contact>
    <investigator>
      <last_name>David Liljenquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MODEL Clinical Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocinology Specialists, Inc.</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzette Christopher, CRC</last_name>
      <phone>314-469-6224</phone>
      <phone_ext>226</phone_ext>
      <email>metabnet@aol.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Oiknine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Javara, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Reyna</last_name>
      <phone>346-237-4868</phone>
      <email>areyna@javararesearch.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Patel, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

